FTC Files Amicus Brief Outlining Anticompetitive Harm Caused by Improper Orange Book Listings
November 21, 2023
November 21, 2023
WASHINGTON, Nov. 21 -- The Federal Trade Commission issued the following news release on Nov. 20, 2023:
The Federal Trade Commission filed an amicus brief to address the anticompetitive harm that stems from improperly listed patents in the Food and Drug Administration's (FDA) publication of "Approved Drug Products with Therapeutic Equivalence Evaluations," commonly known as the "Orange Book."
The Commission's filing relates to an antitrust case broug . . .
The Federal Trade Commission filed an amicus brief to address the anticompetitive harm that stems from improperly listed patents in the Food and Drug Administration's (FDA) publication of "Approved Drug Products with Therapeutic Equivalence Evaluations," commonly known as the "Orange Book."
The Commission's filing relates to an antitrust case broug . . .